Successful Strategies for Diagnostic Method Patents
Requires Subscription or Fee PDF

Keywords

USPTO
patents
diagnostics
patentability
35USC§101

Abstract

This article addresses strategies used to obtain patent protection for diagnostic method patents after the 2012 Mayo decision by the U.S. Supreme Court.

https://doi.org/10.5912/jcb783
Requires Subscription or Fee PDF

References

Mayo Collaborative Services v. Prometheus Laboratories, Inc. 132 S. Ct. 1289 (2012).

Ledford, H. (2016) US personalized-medicine industry takes hit from Supreme Court. Nature 536 (Issue 7617): 382.

Noonan, K. (2016) Diagnostic patents at risk after Federal Circuit decisions. Nature Reviews 15: 377.

United States Code (U.S.C.) Title 35, Section 102.

35 U.S.C. §103.

35 U.S.C. §112.

Diamond v. Diehr, 450 U. S. 175, 187 (1981).

U.S. Patent No. 6,258,540 B1, issued July 10, 2001, Lo et al., Non-invasive prenatal diagnosis.

Ariosa Diagnostics, Inc. v. Sequenom, Inc., 788 F.3d 1371 (Fed. Cir. 2015).

https://www.uspto.gov/sites/default/files/documents/ieg-may-2016-ex.pdf.

Macedo, C.R., Halpern, B.M. and Sebba, M. (2017) ARE Patent Law Alert: USPTO Updates Guidance on Patent Subject Matter Eligibility With New Examples Of Patent-Eligible Subject Matter. https://www.arelaw.com/publications/view/alert011017/.

Macedo, C.R. and Hudak, S.A. (2016) ARE Patent Law Alert:

USPTO Updates Guidance on Patent Subject Matter Eligibility as Federal Circuit Continues to Issue Decisions Finding Patents Eligible under 35 U.S.C. § 101. https://www.arelaw.com/publications/view/alert110416/.

U.S. patents can be searched at the U.S. Patent Office website: http://patft.uspto.gov/.

Akamai Technologies, Inc. v. Limelight Networks, Inc., 797 F.3d 1020 (Fed. Cir. 2015).

Pfizer v. Ranbaxy, 457 F.3d 1284 (Fed. Cir. 2006).

Quinn, G. (2017) IPO adopts resolution supporting legislation to amend 35 U.S.C. § 101. IPWatchdog®. http://www.ipwatchdog.com/2017/01/31/ipo-adopts-resolution-legislation-amend-101/id=77818/.

Amos B. and Miller A.D. (2017) European and U.S. Patents - A Different Diagnosis, manuscript submitted for publication.

Unless specified by prior arrangement, the author agrees to the following terms and assurances:

  1. For myself and on behalf of the other authors listed on this work, I assign to thinkBiotech LLC the copyright* in the contribution for the full term throughout the world.
  2. I/we further give to the following assurances
    1. I am the sole author of the contribution, or, if not, I have the written authority of the other authors to transfer the copyright* to thinkBiotech LLC and give these warranties;
    2. I and (where appropriate) the other authors are entitled to transfer the copyright to thinkBiotech LLC and no one else would be entitled to prevent us from publishing the contribution;
    3. To the best of my/our knowledge, all the facts in the contribution are true and accurate;
    4. The content of the contribution is entirely original to me (and where appropriate to the other authors) or, if not, the written permission of the owner of the copyright in any material copied from elsewhere has been obtained for all media (all such permissions to be attached to the contribution as supplementary files);
    5. Nothing in the contribution is obscene or libellous;
    6. Nothing in the contribution infringes any duty of confidentiality which I/or the other authors may owe to anyone else.
    7. I and/or the other authors have obtained the appropriate clearances from my/our employer(s) or other concerned institution(s).
* Works by US government employees prepared as part of official duties are in the public domain and the authors are therefore exempt from copyright assignment.